EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy

J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J. Kaye, Neal Lindeman, Titus J. Boggon, Katsuhiko Naoki, Hidefumini Sasaki, Yoshitaka Fujii, Michael J. Eck, William R. Sellers, Bruce E. Johnson, Matthew Meyerson

Research output: Contribution to journalArticlepeer-review

8622 Citations (Scopus)


Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that EGFR mutations may predict sensitivity to gefitinib.

Original languageEnglish
Pages (from-to)1497-1500
Number of pages4
Issue number5676
Publication statusPublished - 2004 Jun 4
Externally publishedYes

ASJC Scopus subject areas

  • General


Dive into the research topics of 'EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy'. Together they form a unique fingerprint.

Cite this